^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ALOX12B (Arachidonate 12-Lipoxygenase)

i
Other names: ALOX12B, Arachidonate 12-Lipoxygenase, 12R Type, 12R-LOX, 12R-Lipoxygenase, Arachidonate 12-Lipoxygenase, 12R-Type, Epidermis-Type Lipoxygenase 12, ARCI2
Associations
Trials
16d
ALLOSTERIC PROPERTIES OF MAMMALIAN ALOX15 ORTHOLOGS. (PubMed, J Biol Chem)
Mammalian ALOX15 orthologs are allosteric enzymes but the molecular basis for their allosteric properties remains controversial. In fact, two alternative hypotheses (presence of allosteric binding sites at enzyme monomers vs. ALOX15 dimers consist of an allosteric and a catalytic monomer) have been introduced and this review is aimed at critically evaluating the pros and conts of these two mechanistic scenarios.
Review • Journal
|
ALOX12B (Arachidonate 12-Lipoxygenase) • ALOX15 (Arachidonate 15-Lipoxygenase) • ALOXE3 (Arachidonate Lipoxygenase 3) • ALOX15B (Arachidonate 15-Lipoxygenase Type B)
24d
Describing the Mutational Characteristics of Myxofibrosarcoma: An AACR Project GENIE Analysis. (PubMed, Anticancer Res)
As we enter the era of precision medicine, classifying cancers by molecular markers will become increasingly valuable. Our investigation enriches the literature by identifying novel mutations and mutations exclusive to certain demographic groups. These findings support a shift beyond histology toward molecularly informed diagnostics and pathway-directed therapeutic hypotheses for MFS. Next steps should validate candidate markers in independent cohorts and link genomic profiles to clinicopathologic features, disease course, and treatment response to improve clinical translation. These observations will help shape diagnostics and targeted therapies against MFS.
Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • ETV6 (ETS Variant Transcription Factor 6) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler) • NOTCH3 (Notch Receptor 3) • NCOR1 (Nuclear Receptor Corepressor 1) • FLCN (Folliculin) • ALOX12B (Arachidonate 12-Lipoxygenase) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • NCOA2 (Nuclear Receptor Coactivator 2) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
|
TP53 mutation • CDKN2A deletion
2ms
Mutational Spectrum of T-Cell Large Granular Lymphocytic Leukemia: Insights From the AACR Project GENIE Consortium. (PubMed, Cancer Genomics Proteomics)
This study provides a comprehensive genomic profile of T-LGLL, identifying recurrent somatic mutations and commonly affected pathways. Notably, frequent alterations were observed in the FAS-FASL signaling pathway, underscoring its potential as a target for therapeutic development.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • STAT3 (Signal Transducer And Activator Of Transcription 3) • FASLG (Fas ligand) • IKZF3 (IKAROS Family Zinc Finger 3) • TNFAIP3 (TNF Alpha Induced Protein 3) • EPHB1 (EPH Receptor B1) • SETD1B (SET Domain Containing 1B, Histone Lysine Methyltransferase) • STAT2 (Signal transducer and activator of transcription 2) • ALOX12B (Arachidonate 12-Lipoxygenase) • DDX3X (DEAD-Box Helicase 3 X-Linked)
|
TP53 mutation • STAT3 mutation
3ms
Case Report: Metachronous pancreatic adenocarcinoma following HER2-positive breast cancer and the implications of non-BRCA germline variants with TP53-mutant disease. (PubMed, Front Oncol)
A 54-year-old woman was diagnosed with stage IIIB HER2-positive invasive breast cancer in 2017 and treated with neoadjuvant chemotherapy (TAC), modified radical mastectomy, radiotherapy, trastuzumab, and toremifene...It suggests that VUS in genes involved in cellular stress and metabolic pathways, particularly in combination with TP53 mutations, may contribute to the development of multiple primary malignancies. Furthermore, it underscores the importance of vigilant, phenotype-driven long-term surveillance in such patients, regardless of germline testing results.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • ALOX12B (Arachidonate 12-Lipoxygenase) • CA 19-9 (Cancer antigen 19-9)
|
HER-2 positive • TP53 mutation • ATM mutation • PALB2 mutation
|
Herceptin (trastuzumab)
4ms
Construction of a lipid metabolism-based prognostic gene signature in cervical squamous cell carcinoma and validation of LIPG's oncogenic role. (PubMed, Cancer Cell Int)
The LMPS was a valuable prognostic tool and was correlated with the TME and drug sensitivity. LIPG was a key regulator of lipid metabolism and facilitated CSCC development by hydrolyzing PC into lysophosphatidylcholine (LPC) and activating the MAPK-p38 signaling pathway. These findings may highlight the potential of targeting lipid metabolism for therapeutic intervention in CSCC.
Journal • Gene Signature • IO biomarker
|
ALOX12B (Arachidonate 12-Lipoxygenase)
4ms
Integration of machine learning to reveal the correlation between ferroptosis and M2 macrophages in head and neck squamous cell carcinoma. (PubMed, Discov Oncol)
In this study, we constructed an MFRS model to predict patient prognosis and therapeutic response. This study also preliminarily reveals the roles of M2Ms and ferroptosis in HNSCC patients and provides potentially novel insight for treatment.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • SLC3A2 (Solute Carrier Family 3 Member 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • DDR2 (Discoidin domain receptor 2) • NOX4 (NADPH Oxidase 4) • PRKCA (Protein Kinase C Alpha) • ALOX12B (Arachidonate 12-Lipoxygenase) • ENPP2 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 2)
5ms
Piperine targets SOAT1 to inhibit the progression of esophageal squamous cell carcinoma via ferroptosis. (PubMed, Phytomedicine)
This study is the first to demonstrate that piperine targets SOAT1 to enhance ferroptosis by inhibiting the PI3K-AKT axis and upregulating the expression of KLF4/ALOX12B. This study strongly emphasizes the potential of piperine as a promising clinical therapeutic candidate for ESCC.
Journal
|
KLF4 (Kruppel-like factor 4) • ALOX12 (Arachidonate 12-Lipoxygenase, 12S Type) • ALOX12B (Arachidonate 12-Lipoxygenase)
|
cisplatin
11ms
Comprehensive analysis of metabolism-related gene biomarkers reveals their impact on the diagnosis and prognosis of triple-negative breast cancer. (PubMed, BMC Cancer)
This study established a robust prognostic model capable of accurately predicting clinical outcomes and metastasis, which could aid in personalized clinical decision-making.
Journal • IO biomarker
|
IDO1 (Indoleamine 2,3-dioxygenase 1) • ALOX12B (Arachidonate 12-Lipoxygenase)
12ms
Molecular insights into genodermatoses: Genetic findings from 43 patients. (PubMed, Arch Dermatol Res)
The mean age at diagnosis varied significantly among conditions, reflecting the diagnostic challenges and clinical variability of genodermatoses. This study emphasizes the critical role of WES and CES in diagnosing genodermatoses and understanding their molecular basis, which enhances diagnostic accuracy and supports personalized management strategies.
Journal
|
PTEN (Phosphatase and tensin homolog) • NF1 (Neurofibromin 1) • ST14 (ST14 transmembrane serine protease matriptase) • ALOX12B (Arachidonate 12-Lipoxygenase) • COL17A1 (Collagen Type XVII Alpha 1 Chain) • ITGB4 (Integrin Subunit Beta 4)
over1year
OMICHTYOSE: Study of in Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis (clinicaltrials.gov)
P=N/A, N=18, Completed, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Completed | Trial completion date: Feb 2023 --> Apr 2024 | Trial primary completion date: Feb 2023 --> Apr 2024
Trial completion • Trial completion date • Trial primary completion date
|
ABCA1 (ATP Binding Cassette Subfamily A Member 1) • ALOX12B (Arachidonate 12-Lipoxygenase)
over1year
Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma. (PubMed, Cancer Immunol Immunother)
Furthermore, the results of immunofluorescence double staining showed that patients with high risk scores had a significantly higher level of M2 macrophage than those with low risk scores (p < 0.05). In conclusion, our study provides insights into the genomic landscape of ESCC and highlights the prognostic value of a genomic mutation signature associated with the immune microenvironment in southern Chinese patients with ESCC.
Journal • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • IFNG (Interferon, gamma) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • KMT2C (Lysine Methyltransferase 2C) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • FAT1 (FAT atypical cadherin 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • ITGB2 (Integrin Subunit Beta 2) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • TNFSF4 (TNF Superfamily Member 4) • ALOX12 (Arachidonate 12-Lipoxygenase, 12S Type) • ALOX12B (Arachidonate 12-Lipoxygenase) • BTN3A1 (Butyrophilin Subfamily 3 Member A1) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
over1year
A novel fatty acid metabolism-related signature identifies MUC4 as a novel therapy target for esophageal squamous cell carcinoma. (PubMed, Sci Rep)
Our study fills the gap of FMGs signature in predicting the prognosis of ESCC patients. These findings revealed that cluster subtypes and risk model of FMGs had effects on survival prediction, and were expected to be the potential promising targets for ESCC.
Journal
|
MUC4 (Mucin 4, Cell Surface Associated) • ALOX12B (Arachidonate 12-Lipoxygenase) • BAALC (BAALC Binder Of MAP3K1 And KLF4) • FZD10 (Frizzled Class Receptor 10) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)